Clinical trial
Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy
NCT04034485 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy
- Lead sponsor
- LIB Therapeutics LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 7, 2019
- Completion date
- January 30, 2023
- Enrollment
- 65 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.